| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 10 | 2023 | 2174 | 1.110 |
Why?
|
| Liver Neoplasms | 11 | 2023 | 4805 | 0.970 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2021 | 408 | 0.840 |
Why?
|
| Health Services for Transgender Persons | 1 | 2021 | 1 | 0.800 |
Why?
|
| Sex Reassignment Procedures | 1 | 2021 | 19 | 0.790 |
Why?
|
| Gender Identity | 1 | 2021 | 79 | 0.760 |
Why?
|
| Veterans | 7 | 2024 | 1778 | 0.730 |
Why?
|
| Transgender Persons | 1 | 2021 | 62 | 0.720 |
Why?
|
| Patient Transfer | 1 | 2021 | 136 | 0.710 |
Why?
|
| Natural Language Processing | 2 | 2024 | 119 | 0.700 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 4967 | 0.700 |
Why?
|
| Adenocarcinoma | 8 | 2020 | 7971 | 0.700 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 5209 | 0.680 |
Why?
|
| Stomach Neoplasms | 3 | 2021 | 2317 | 0.620 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 321 | 0.610 |
Why?
|
| Exercise Therapy | 1 | 2021 | 292 | 0.610 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 736 | 0.590 |
Why?
|
| Gastrectomy | 2 | 2021 | 476 | 0.550 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 917 | 0.550 |
Why?
|
| Cancer Survivors | 2 | 2021 | 743 | 0.540 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 115 | 0.510 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 95 | 0.500 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 130 | 0.500 |
Why?
|
| Lymph Nodes | 5 | 2019 | 3069 | 0.480 |
Why?
|
| Fatigue | 1 | 2021 | 1280 | 0.470 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 3976 | 0.430 |
Why?
|
| Electronic Health Records | 3 | 2024 | 969 | 0.420 |
Why?
|
| Hospitals | 3 | 2020 | 491 | 0.380 |
Why?
|
| Databases, Factual | 3 | 2018 | 2287 | 0.360 |
Why?
|
| HIV Infections | 1 | 2023 | 2156 | 0.360 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1240 | 0.340 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 210 | 0.330 |
Why?
|
| Physician's Role | 1 | 2011 | 231 | 0.320 |
Why?
|
| Communication | 2 | 2022 | 854 | 0.270 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 13989 | 0.270 |
Why?
|
| Aged | 26 | 2024 | 73421 | 0.270 |
Why?
|
| Retrospective Studies | 16 | 2023 | 39731 | 0.250 |
Why?
|
| Algorithms | 1 | 2016 | 3922 | 0.240 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 624 | 0.240 |
Why?
|
| Primary Health Care | 1 | 2011 | 842 | 0.240 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 5113 | 0.240 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5996 | 0.230 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 14653 | 0.230 |
Why?
|
| Middle Aged | 21 | 2024 | 90349 | 0.220 |
Why?
|
| Male | 26 | 2024 | 128836 | 0.220 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 71 | 0.220 |
Why?
|
| Esophagectomy | 2 | 2018 | 947 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 2270 | 0.210 |
Why?
|
| United States | 12 | 2021 | 16036 | 0.210 |
Why?
|
| Humans | 36 | 2024 | 271636 | 0.210 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 1033 | 0.200 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 31032 | 0.200 |
Why?
|
| Frailty | 1 | 2024 | 131 | 0.190 |
Why?
|
| Female | 24 | 2024 | 148992 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6266 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2016 | 441 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 9042 | 0.170 |
Why?
|
| Emotions | 2 | 2021 | 556 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2019 | 295 | 0.160 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 2029 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 562 | 0.150 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 1443 | 0.140 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 44 | 0.140 |
Why?
|
| Comorbidity | 3 | 2019 | 2435 | 0.140 |
Why?
|
| Veterans Health | 1 | 2018 | 179 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 16606 | 0.130 |
Why?
|
| Hospice Care | 1 | 2018 | 160 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 108 | 0.130 |
Why?
|
| Adult | 11 | 2021 | 81791 | 0.130 |
Why?
|
| Stomach | 1 | 2019 | 405 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 479 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2019 | 33846 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 333 | 0.130 |
Why?
|
| Telemedicine | 1 | 2022 | 546 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 3697 | 0.130 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 245 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 1255 | 0.120 |
Why?
|
| Motor Activity | 1 | 2019 | 718 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 329 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 677 | 0.120 |
Why?
|
| Young Adult | 5 | 2021 | 22094 | 0.120 |
Why?
|
| Esophageal Neoplasms | 2 | 2018 | 3240 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 364 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1827 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2019 | 2335 | 0.110 |
Why?
|
| Registries | 2 | 2019 | 2246 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2021 | 9467 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2019 | 1550 | 0.100 |
Why?
|
| Pancreatectomy | 1 | 2017 | 696 | 0.100 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 498 | 0.100 |
Why?
|
| Adolescent | 5 | 2021 | 32609 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 501 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 3852 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1322 | 0.100 |
Why?
|
| Neoplasms | 4 | 2024 | 15903 | 0.100 |
Why?
|
| Palliative Care | 2 | 2018 | 2156 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 629 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 2202 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 5601 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10259 | 0.090 |
Why?
|
| Patient Care Management | 1 | 2011 | 94 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1089 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4998 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 605 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 106 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 469 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2013 | 937 | 0.080 |
Why?
|
| Gait | 2 | 2021 | 158 | 0.080 |
Why?
|
| Perception | 1 | 2011 | 351 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 380 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2011 | 628 | 0.070 |
Why?
|
| Inpatients | 1 | 2013 | 695 | 0.070 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1335 | 0.070 |
Why?
|
| Quinazolines | 1 | 2012 | 953 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 5195 | 0.070 |
Why?
|
| Attitude to Death | 1 | 2008 | 102 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2008 | 96 | 0.070 |
Why?
|
| Quality of Life | 1 | 2021 | 4745 | 0.070 |
Why?
|
| Piperidines | 1 | 2012 | 1090 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2017 | 9323 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2011 | 829 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2008 | 439 | 0.060 |
Why?
|
| Fear | 2 | 2021 | 259 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 2443 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4495 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2017 | 3539 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2011 | 1462 | 0.050 |
Why?
|
| Survival Rate | 3 | 2021 | 12530 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 5919 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 5566 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 1038 | 0.050 |
Why?
|
| Prognosis | 1 | 2018 | 22525 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 5246 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 10354 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 143 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 5180 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2952 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4352 | 0.040 |
Why?
|
| Postural Balance | 1 | 2019 | 141 | 0.040 |
Why?
|
| Attention | 1 | 2019 | 285 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 12219 | 0.040 |
Why?
|
| Diplopia | 1 | 2017 | 48 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2019 | 295 | 0.030 |
Why?
|
| Exercise | 1 | 2024 | 1214 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 12008 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 758 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 2853 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 6876 | 0.030 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 64 | 0.030 |
Why?
|
| Health Services | 1 | 2016 | 101 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 256 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1173 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 835 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 5509 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 192 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 421 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1603 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 70 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 5111 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 10743 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 374 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 235 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1740 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 503 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 916 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 18016 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 2045 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 1154 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 4070 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 994 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6230 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 18 | 0.020 |
Why?
|
| Existentialism | 1 | 2008 | 9 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 641 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4391 | 0.020 |
Why?
|
| Grief | 1 | 2008 | 32 | 0.020 |
Why?
|
| New York | 1 | 2008 | 104 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2013 | 551 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 16226 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 129 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3423 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 279 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1588 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 3460 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 250 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2495 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 13116 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1227 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 559 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1072 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2672 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1060 | 0.010 |
Why?
|
| Family | 1 | 2008 | 778 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 2267 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2012 | 2383 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 3416 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6905 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 15254 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 4963 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 13385 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 9093 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 62757 | 0.000 |
Why?
|